drugset
Drugs / MTX325
last change Oct 2025 re-read 3 minutes ago

MTX325

Developed for
Parkinson disease

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 1 NCT07630545 Comparator Nov 2023 → Jun 2027 expected Parkinson disease Mission Therapeutics Recruiting No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2025-10-15 Mission Therapeutics Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials missiontherapeutics.com ↗
2024-07-02 Mission Therapeutics Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325 missiontherapeutics.com ↗
2024-03-21 Mission Therapeutics Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease missiontherapeutics.com ↗
2023-12-05 Mission Therapeutics Mission Therapeutics granted MHRA Clinical Trial Authorisation (CTA) for MTX325 for the treatment of Parkinson’s Disease missiontherapeutics.com ↗
2023-11-13 Mission Therapeutics Mission Therapeutics announces publication in Nature Communications outlining potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson’s Disease missiontherapeutics.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MTX325 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07630545 ↗
Route Oral “MTX325 Active Oral Capsules - 1.5mg - 100mg” NCT07630545 ↗